About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AKBA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in…
NCT06901505 · Anemia of Chronic Kidney Disease
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
AKBA
Akebia Therapeutics
Phase 3Completed353Aug 12, 2026Registry ↗
Nov 9, 2026A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638 · Focal Segmental Glomerulosclerosis
Praliciguat (Part A), Placebo (Part A)
AKBA
Akebia Therapeutics
Phase 2Recruiting60Jun 2027Registry ↗
Oct 6, 2026SAD and MAD Study of AKB-9090 in Healthy Adult Participants
NCT07429006 · Healthy Volunteers
AKB-9090, Placebo
AKBA
Akebia Therapeutics
Phase 1Recruiting44Dec 2026Registry ↗
Oct 1, 2026A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants Wi…
NCT06419205 · IgA Nephropathy, Lupus Nephritis (LN)
ADX-097
AKBA
Akebia Therapeutics
Phase 2Recruiting30Feb 2028Registry ↗
Oct 1, 2025Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia…
NCT05082584 · Anemia of Chronic Kidney Disease
Vadadustat
AKBA
Akebia Therapeutics
Phase 3Withdrawn0Jul 2026Registry ↗
Oct 1, 2025Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia…
NCT05082571 · Anemia of Chronic Kidney Disease
vadadustat
AKBA
Akebia Therapeutics
Phase 3Withdrawn0Jul 2026Registry ↗
May 22, 2025Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly…
NCT04313153 · Anemia
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Completed319Nov 26, 2021Registry ↗
Jan 15, 2025Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimu…
NCT04707768 · Anemia Associated With Chronic Kidney Disease (CKD)
Vadadustat, Mircera®
AKBA
Akebia Therapeutics
Phase 3Completed456Jan 6, 2023Registry ↗
Sep 29, 2022Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
NCT03799627 · Anemia, Dialysis-dependent Chronic Kidney Disease
Vadadustat, Epoetin Alfa
AKBA
Akebia Therapeutics
Phase 2Completed175Jun 5, 2020Registry ↗
Sep 15, 2022A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Prese…
NCT03254485 · Heart Failure With Preserved Ejection Fraction
IW-1973, Placebo Oral Tablet
AKBA
Akebia Therapeutics
Phase 2Completed196Aug 19, 2019Registry ↗
Sep 15, 2022A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy…
NCT03217591 · Type 2 Diabetes Mellitus With Diabetic Nephropathy
IW-1973, IW-1973
AKBA
Akebia Therapeutics
Phase 2Completed156Aug 20, 2019Registry ↗
Jul 21, 202220-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01906489 · Anemia, Chronic Kidney Disease
AKB-6548, Placebo
AKBA
Akebia Therapeutics
Phase 2Completed210Sep 3, 2014Registry ↗
Jul 18, 2022Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Ane…
NCT02865850 · Anemia, Dialysis-Dependent Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Completed369Jan 31, 2020Registry ↗
Jul 1, 202216-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease…
NCT02260193 · Anemia, End Stage Renal Disease
AKB-6548, AKB-6548
AKBA
Akebia Therapeutics
Phase 2Completed94Jul 22, 2015Registry ↗
Jul 1, 202242-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01381094 · Anemia, Kidney Disease
AKB-6548, Placebo
AKBA
Akebia Therapeutics
Phase 2Completed93Feb 16, 2012Registry ↗
Jul 1, 2022Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01235936 · Anemia, Kidney Disease
AKB-6548
AKBA
Akebia Therapeutics
Phase 2Completed10Apr 13, 2011Registry ↗
Jun 28, 2022Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Dis…
NCT04707573 · Chronic Kidney Disease
Vadadustat
AKBA
Akebia Therapeutics
Phase 2Completed22Sep 24, 2010Registry ↗
Jun 28, 2022Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Partici…
NCT02892149 · Anemia, Dialysis-Dependent Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Completed3,554Jan 16, 2020Registry ↗
Jun 27, 2022Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Partici…
NCT02680574 · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Completed1,725Jun 18, 2020Registry ↗
Jun 27, 2022Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-depende…
NCT02648347 · Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Completed1,751Jun 4, 2020Registry ↗
Apr 8, 2021Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent C…
NCT03054350 · Anemia, Dialysis Dependent Chronic Kidney Disease
Vadadustat, Placebo
AKBA
Akebia Therapeutics
Phase 2Completed60Oct 24, 2017Registry ↗
Apr 8, 2021Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Depende…
NCT03054337 · Anemia, Non-dialysis Dependent Chronic Kidney Disease
Vadadustat, Placebo
AKBA
Akebia Therapeutics
Phase 2Completed51Jul 4, 2017Registry ↗
Feb 21, 2021Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease…
NCT03140722 · Anemia, Dialysis-Dependent Chronic Kidney Disease
vadadustat, epoetin alfa
AKBA
Akebia Therapeutics
Phase 2Terminated2Mar 21, 2018Registry ↗
Oct 8, 2020Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics o…
NCT04299633 · Healthy Volunteers
Vadadustat, Sevelamer carbonate
AKBA
Akebia Therapeutics
Phase 1Completed54Aug 2, 2020Registry ↗
Sep 16, 2020Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis…
NCT03992066 · Anemia Associated With Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 1Completed46May 5, 2020Registry ↗
Mar 22, 2019Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
NCT03801759 · Drug Interaction Potentiation
Vadadustat, Furosemide
AKBA
Akebia Therapeutics
Phase 1Completed62Sep 30, 2018Registry ↗
Mar 22, 2019Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
NCT03801746 · Drug Interaction Potentiation
vadadustat, Rifampin
AKBA
Akebia Therapeutics
Phase 1Completed40Aug 15, 2018Registry ↗
Mar 22, 2019Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastat…
NCT03801733 · Drug Interaction Potentiation
Vadadustat, Simvastatin
AKBA
Akebia Therapeutics
Phase 1Completed134Nov 24, 2018Registry ↗
Mar 22, 2019A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
NCT03799848 · Hepatic Impairment
Vadadustat
AKBA
Akebia Therapeutics
Phase 1Completed24Oct 18, 2018Registry ↗
Mar 22, 2019Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
NCT03789032 · Drug Interaction Potentiation, Pharmacokinetics
Vadadustat, Rabeprazole
AKBA
Akebia Therapeutics
Phase 1Completed20Nov 9, 2018Registry ↗
Mar 22, 2019A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and…
NCT03657290 · Healthy
vadadustat
AKBA
Akebia Therapeutics
Phase 1Completed54Oct 16, 2018Registry ↗
Mar 22, 2019A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets…
NCT03639155 · Healthy
vadadustat reference tablets, vadadustat test tablets
AKBA
Akebia Therapeutics
Phase 1Completed50May 23, 2018Registry ↗
Nov 14, 2018Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
NCT02502500 · Healthy Volunteers
Celecoxib, AKB-6548
AKBA
Akebia Therapeutics
Phase 1Completed12Jul 2015Registry ↗
Nov 14, 2018Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Hea…
NCT02412449 · Healthy
AKB-6548 tablet, reference formulation given in the fasted…
AKBA
Akebia Therapeutics
Phase 1Completed18Apr 2015Registry ↗
Nov 14, 2018Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
NCT02327546 · Healthy Volunteers
AKB-6548, Ferrous Sulfate
AKBA
Akebia Therapeutics
Phase 1Completed10Dec 2014Registry ↗
Nov 14, 2018Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
NCT02062203 · Healthy Volunteers
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dos…
AKBA
Akebia Therapeutics
Phase 1Completed50Apr 2014Registry ↗
Nov 5, 2018Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With…
NCT03242967 · Anemia, Dialysis-Dependent Chronic Kidney Disease
Vadadustat, Darbepoetin alfa
AKBA
Akebia Therapeutics
Phase 3Withdrawn0Feb 12, 2018Registry ↗

37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:24 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances